SCHEMBL7065071 — predicted protein targets

Known targets — ChEMBL curated mechanism

ABL1 BMX BRAF BTK CHRNA4 CHRNB2 CSNK1E EGFR ERBB2 F10 FLT1 FLT3 FLT4 IGF1R INSR ITK JAK3 KDR KIT OPRM1 PARP1 PARP2 PDGFRB PIK3CD RAF1 RET SLC18A2 TEC TXK dacA dacB dacC ftsI mrcA mrcB mrdA rplA rplB rplC rplD rplE rplF rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmF rpmG rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	ERN1	O75460	1/20	0.41

▸	MAPT	P10636	4/20	0.38

▸	MEN1	O00255	2/20	0.38

▸	KMT2A	Q03164	2/20	0.38

▸	POLB	P06746	1/20	0.38

▸	PPARG	P37231	1/20	0.36

▸	CHRNA7	P36544	1/20	0.35

▸	CA1	P00915	2/20	0.35

▸	CA2	P00918	2/20	0.35

▸	CA12	O43570	1/20	0.35

▸	CA9	Q16790	1/20	0.35

▸	CYP2D6	P10635	1/20	0.35

▸	MAPK1	P28482	1/20	0.35

▸	GFER	P55789	1/20	0.35

▸	CYP2C9	P11712	2/20	0.35

▸	CYP2C19	P33261	2/20	0.35

▸	NPSR1	Q6W5P4	1/20	0.35

▸	PTGS2	P35354	4/20	0.34

▸	ALDH1A1	P00352	3/20	0.34

▸	KDM4E	B2RXH2	1/20	0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL7065076	1.00	ERN1 (0.41)	ERN1MAPTMEN1KMT2APOLB
SCHEMBL7059994	0.94	MAPT (0.38)	MAPTMEN1KMT2APOLBCA1
SCHEMBL7060001	0.94	MAPT (0.38)	MAPTMEN1KMT2APOLBCA1
SCHEMBL7066431	0.85	CA2 (0.46)	MAPTMEN1KMT2APOLBPPARG
SCHEMBL7066433	0.85	CA2 (0.46)	MAPTMEN1KMT2APOLBPPARG
SCHEMBL7065228	0.83	PTGS2 (0.50)	MAPTMEN1KMT2AMAPK1GFER
SCHEMBL7065223	0.83	PTGS2 (0.50)	MAPTMEN1KMT2AMAPK1GFER
Water SCHEMBL7064901	0.82	MAPK1 (0.43)	MAPTMEN1KMT2ACA1CA2
Water SCHEMBL7064903	0.82	MAPK1 (0.43)	MAPTMEN1KMT2ACA1CA2
SCHEMBL7065078	0.82	ERN1 (0.41)	ERN1MAPTMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20120178820-A1	METHOD FOR TREATING ARTHRITIS	ANAMAR AB (SE)	2012-07-12	—	—	US	disclosed
EP-1313461-A2	THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS	Melacure Therapeutics AB (SE)	2003-05-28	—	—	EP	disclosed
WO-2002011715-A2	THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS	MELACURE THERAPEUTICS AB (SE)	2002-02-14	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120178820-A1	METHOD FOR TREATING ARTHRITIS	MC5R, MC1R, MC2R	ERN1 4450/4885MAPT 3995/4885MEN1 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.